NO912418D0 - Metode for behandling av blaerekanserceller. - Google Patents
Metode for behandling av blaerekanserceller.Info
- Publication number
- NO912418D0 NO912418D0 NO912418A NO912418A NO912418D0 NO 912418 D0 NO912418 D0 NO 912418D0 NO 912418 A NO912418 A NO 912418A NO 912418 A NO912418 A NO 912418A NO 912418 D0 NO912418 D0 NO 912418D0
- Authority
- NO
- Norway
- Prior art keywords
- cancer cells
- chelating
- treatment
- usually
- sulphate
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/495—Transforming growth factor [TGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/6415—Toxins or lectins, e.g. clostridial toxins or Pseudomonas exotoxins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/642—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a cytokine, e.g. IL2, chemokine, growth factors or interferons being the inactive part of the conjugate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/21—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Pseudomonadaceae (F)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Networks Using Active Elements (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US54228190A | 1990-06-21 | 1990-06-21 | |
| US66926991A | 1991-03-14 | 1991-03-14 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| NO912418D0 true NO912418D0 (no) | 1991-06-20 |
| NO912418L NO912418L (no) | 1991-12-23 |
| NO303579B1 NO303579B1 (no) | 1998-08-03 |
Family
ID=27066985
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO912418A NO303579B1 (no) | 1990-06-21 | 1991-06-20 | FremgangsmÕte for fremstilling av et TGF-<alfa>-PE40-hybridprotein |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US5690928A (no) |
| EP (2) | EP0467536B1 (no) |
| JP (1) | JPH0721000B2 (no) |
| KR (1) | KR920000332A (no) |
| AT (1) | ATE173274T1 (no) |
| AU (1) | AU645094B2 (no) |
| CA (1) | CA2044858A1 (no) |
| DE (1) | DE69130466T2 (no) |
| DK (1) | DK0467536T3 (no) |
| ES (1) | ES2122968T3 (no) |
| FI (1) | FI913058A (no) |
| IE (1) | IE912130A1 (no) |
| IL (1) | IL98528A0 (no) |
| NO (1) | NO303579B1 (no) |
| PT (1) | PT98048B (no) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6207798B1 (en) * | 1989-08-03 | 2001-03-27 | Merck & Co., Inc. | Modified PE40 toxin fusion proteins |
| JPH06509563A (ja) * | 1991-07-05 | 1994-10-27 | セラゲン・インコーポレイテッド | 炎症性関節炎の治療用の表皮細胞成長因子受容体を標的とする分子 |
| CA2146572A1 (en) * | 1992-10-07 | 1994-04-14 | Dorothy Marquis-Omer | Controlled-ph formulation for intravesicular instillation of tgfpe40 ab |
| JP2002543096A (ja) * | 1999-04-26 | 2002-12-17 | ステム セル ファーマシューティカルズ，インコーポレーテッド | ＴＧＦ−αポリペプチド、機能性断片およびそれらの利用法 |
| US20020193301A1 (en) * | 1999-08-19 | 2002-12-19 | Stem Cell Pharmaceuticals, Inc. | TGF-alpha polypeptides, functional fragments and methods of use therefor |
| WO2001012127A2 (en) * | 1999-08-19 | 2001-02-22 | Stem Cell Pharmaceuticals, Inc. | TGF-α POLYPEPTIDES, FUNCTIONAL FRAGMENTS AND METHODS OF USE THEREFOR |
| CU23077A1 (es) * | 2000-12-06 | 2005-08-17 | Centro Inmunologia Molecular | Composicion vacunal que contiene factor de crecimiento transformante (tgf-alfa). su uso en la terapia de enfermedades malignas |
| PL2382990T3 (pl) * | 2003-04-30 | 2015-04-30 | Univ Zuerich | Sposoby leczenia raka z zastosowaniem immunotoksyny |
| CN100436481C (zh) * | 2003-08-18 | 2008-11-26 | 中国医学科学院基础医学研究所 | 含腺病毒E4orf4蛋白的靶向性抗肿瘤融合蛋白 |
| GB0321344D0 (en) * | 2003-09-11 | 2003-10-15 | Health Prot Agency | Re-targeted toxin conjugates |
| PT1853250E (pt) * | 2005-02-18 | 2012-02-03 | Abraxis Bioscience Llc | Combinações e modos de administração de agentes terapêuticos e terapia de combinação |
| US20070166388A1 (en) | 2005-02-18 | 2007-07-19 | Desai Neil P | Combinations and modes of administration of therapeutic agents and combination therapy |
| US8735394B2 (en) | 2005-02-18 | 2014-05-27 | Abraxis Bioscience, Llc | Combinations and modes of administration of therapeutic agents and combination therapy |
| AU2007334360B2 (en) | 2006-12-14 | 2013-10-17 | Abraxis Bioscience, Llc | Breast cancer therapy based on hormone receptor status with nanoparticles comprising taxane |
| MX364637B (es) | 2010-03-29 | 2019-05-03 | Abraxis Bioscience Llc Star | Platino y nanopartículas que incluyen placlitaxel/albúmina para usarse en el trartamiento de nsclc. |
| CA2794147A1 (en) | 2010-03-29 | 2011-10-06 | Abraxis Bioscience, Llc | Use of a composition comprising nanoparticles comprising a taxane and an albumin to improve uptake of chemotherapeutics by tumors and for treating a cancer that is highly fibrotic and/or has a dense stroma |
| KR20190130050A (ko) | 2010-06-04 | 2019-11-20 | 아브락시스 바이오사이언스, 엘엘씨 | 췌장암의 치료 방법 |
| JP2017504621A (ja) | 2013-10-02 | 2017-02-09 | ヴィヴェンティア バイオ インコーポレイテッド | 抗ｅｐｃａｍ抗体及び使用方法 |
| ITUD20130127A1 (it) * | 2013-10-04 | 2015-04-05 | Danieli Off Mecc | Impianto siderurgico per la produzione di prodotti metallici lunghi e relativo metodo di produzione |
| CA2979394A1 (en) | 2015-03-12 | 2016-09-15 | Viventia Bio Inc. | Methods of treatment for epcam positive bladder cancer |
| JP6847846B2 (ja) | 2015-03-12 | 2021-03-24 | セセン バイオ，インコーポレイテッド | Ｅｐｃａｍ陽性膀胱癌を標的とする投薬戦略 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU573529B2 (en) * | 1982-05-12 | 1988-06-16 | President And Fellows Of Harvard College | Hybrid proteins |
| FI82266C (fi) * | 1982-10-19 | 1991-02-11 | Cetus Corp | Foerfarande foer framstaellning av il-2 -mutein. |
| US4518584A (en) * | 1983-04-15 | 1985-05-21 | Cetus Corporation | Human recombinant interleukin-2 muteins |
| US4664911A (en) * | 1983-06-21 | 1987-05-12 | Board Of Regents, University Of Texas System | Immunotoxin conjugates employing toxin B chain moieties |
| US4545985A (en) * | 1984-01-26 | 1985-10-08 | The United States Of America As Represented By The Secretary, Dept. Of Health And Human Services | Pseudomonas exotoxin conjugate immunotoxins |
| EP0154434B1 (en) * | 1984-02-17 | 1993-01-27 | Genentech, Inc. | Human transforming growth factor and precursor or fragment thereof, cells, dna, vectors and methods for their production, compositions and products containing them, and related antibodies and diagnostic methods |
| US4785079A (en) * | 1984-11-09 | 1988-11-15 | The Salk Institute For Biological Studies | Isolation of fibroblast growth factor |
| IN165717B (no) * | 1986-08-07 | 1989-12-23 | Battelle Memorial Institute | |
| US4892827A (en) * | 1986-09-24 | 1990-01-09 | The United States Of America As Represented By The Department Of Health And Human Services | Recombinant pseudomonas exotoxins: construction of an active immunotoxin with low side effects |
| ATE133993T1 (de) * | 1989-02-17 | 1996-02-15 | Merck & Co Inc | Protein-antikrebsmittel |
| NZ232900A (en) * | 1989-03-22 | 1993-08-26 | Merck & Co Inc | Pseudomonas exotoxin a, pe 40 domain derivatives |
-
1991
- 1991-06-17 IL IL98528A patent/IL98528A0/xx unknown
- 1991-06-18 CA CA002044858A patent/CA2044858A1/en not_active Abandoned
- 1991-06-20 AU AU79189/91A patent/AU645094B2/en not_active Ceased
- 1991-06-20 PT PT98048A patent/PT98048B/pt not_active IP Right Cessation
- 1991-06-20 FI FI913058A patent/FI913058A/fi not_active Application Discontinuation
- 1991-06-20 ES ES91305582T patent/ES2122968T3/es not_active Expired - Lifetime
- 1991-06-20 NO NO912418A patent/NO303579B1/no not_active IP Right Cessation
- 1991-06-20 EP EP91305582A patent/EP0467536B1/en not_active Expired - Lifetime
- 1991-06-20 AT AT91305582T patent/ATE173274T1/de active
- 1991-06-20 DK DK91305582T patent/DK0467536T3/da active
- 1991-06-20 DE DE69130466T patent/DE69130466T2/de not_active Expired - Fee Related
- 1991-06-20 EP EP98106872A patent/EP0868920A3/en not_active Withdrawn
- 1991-06-20 IE IE213091A patent/IE912130A1/en unknown
- 1991-06-21 JP JP3266746A patent/JPH0721000B2/ja not_active Expired - Lifetime
- 1991-06-21 KR KR1019910010286A patent/KR920000332A/ko not_active Application Discontinuation
-
1994
- 1994-04-11 US US08/224,422 patent/US5690928A/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| JPH0592999A (ja) | 1993-04-16 |
| EP0868920A2 (en) | 1998-10-07 |
| IE912130A1 (en) | 1992-01-01 |
| IL98528A0 (en) | 1992-07-15 |
| NO912418L (no) | 1991-12-23 |
| DE69130466T2 (de) | 1999-06-02 |
| EP0467536A3 (en) | 1992-09-16 |
| ATE173274T1 (de) | 1998-11-15 |
| NO303579B1 (no) | 1998-08-03 |
| ES2122968T3 (es) | 1999-01-01 |
| AU645094B2 (en) | 1994-01-06 |
| EP0868920A3 (en) | 1999-02-10 |
| EP0467536B1 (en) | 1998-11-11 |
| DE69130466D1 (de) | 1998-12-17 |
| US5690928A (en) | 1997-11-25 |
| EP0467536A2 (en) | 1992-01-22 |
| DK0467536T3 (da) | 1999-07-26 |
| CA2044858A1 (en) | 1991-12-22 |
| JPH0721000B2 (ja) | 1995-03-08 |
| KR920000332A (ko) | 1992-01-29 |
| PT98048B (pt) | 1998-11-30 |
| FI913058A (fi) | 1991-12-22 |
| FI913058A0 (fi) | 1991-06-20 |
| AU7918991A (en) | 1992-01-02 |
| PT98048A (pt) | 1992-04-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO912418D0 (no) | Metode for behandling av blaerekanserceller. | |
| ES2048548T3 (es) | Procedimiento para la preparacion de las soluciones acuosas con contenido en sulfuro de hidrogeno, en acido cianhidrico y en amoniaco. | |
| Matsuda et al. | Dissociation of tetanus neurotoxin into two polypeptide fragments | |
| DK0447585T4 (da) | Fremgangsmåde til fremstilling af et intravenøst tolerant immunglobulin-G-præparat | |
| FR2562539B1 (fr) | Nouveaux derives de l'acide vinyl-4 benzoique, leur procede de preparation et leurs applications en therapeutique et comme ligands | |
| DK1014996T3 (da) | Præparater indeholdende saccharid til behandling af Alzheimers sygdom og andre amyloidoser | |
| ES2227527T3 (es) | Un factor de crecimiento de queratinocitos (kgf) truncado que tiene actividad biologica aumentada. | |
| ATE135712T1 (de) | Polypeptid, dessen verfahren zur herstellung und dieses enthaltende pharmazeutische zusammensetzung und deren benutzung | |
| ATE123947T1 (de) | Echinacea-extrakte, verfahren zur herstellung und zubereitungen, die sie enthalten. | |
| ATE160561T1 (de) | L-carnitin-salz, dieses enthaltende kosmetische und pharmazeutische zusammensetzungen zur behandlung von dermatosen | |
| BR9104997A (pt) | Complexos ligados em ponte a hidrogenio,processo para sua preparacao farmaceutica | |
| FI892061A0 (fi) | Menetelmä, jonka avulla voidaan valmistaa ferrikloridia lähtemällä ferrokloridista | |
| FR2632302B1 (fr) | Procede de recuperation d'acide citrique a partir d'une liqueur en contenant | |
| ATE168988T1 (de) | L-carnitin-salz, dieses enthaltende kosmetische und pharmazeutische zusammensetzungen zur behandlung von dermatosen | |
| DE69122960D1 (de) | Verfahren und zubereitungen für die behandlung von verletzungen | |
| FR2446839A1 (fr) | Procede de purification de la gamma-globuline s-sulfonee | |
| LU90992I2 (fr) | Xigris-drotrécogine alfa(activée) et ses dérivés hpharmaceutiquement acceptables | |
| ES2161726T3 (es) | Formas amorfas monoesfericas de derivados de insulina. | |
| ATE271896T1 (de) | Salbe enthaltend mometason-furoat und salicylsäure zur topischen behandlung von psoriasis | |
| RU93003584A (ru) | Способ лечения синдрома поликистозных яичников | |
| UA39895C2 (uk) | Аустенітна сульфована нержавіюча сталь з покращеною здатністю до обробки | |
| EA199600048A3 (ru) | N,n-диэтил-8,8-дипропил-2-азаспиро[4,5]декан-2-пропанамин дималеат, фармацевтическая композиция на его основе и способ индуцирования иммуномодуляции | |
| ATE5406T1 (de) | 2-methyl-3-(2,4,6-trijod-3-(1morpholino[thylidenamino)-benzamido)propionitril, verfahren zu dessen herstellung und dessen verwendung als zwischenprodukt. | |
| ES1003038U (es) | Dispositivo corrector de patologia vertebral | |
| Kalinichenko | Initial Microperiphyton Production in the Reservoir/Coolant of an Atomic Power Station(Pervichnaia Produktsiia Mikroperifitona Vodoema-Okhladitelya Atommoi Elektrostantsii) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM1K | Lapsed by not paying the annual fees |
Free format text: LAPSED IN DECEMBER 2003 |